Skip to main content

NCBiotech News

  • Bioscience briefs with names making news
  • Two North Carolina companies are among 39 biotechnology firms competing in a Buzz of BIO contest to recognize the most innovative companies prior to this summer’s BIO International Convention in San Francisco, June 6-9.
  • Bayer's crop science division hosted more than 160 fifth graders and high school students from central North Carolina this week at its Research Triangle Park campus, letting the students tour facilities, talked with Bayer staff and participate in hands-on exercises demonstrating how new crop seeds and ag chemicals move from an idea in someone’s mind to a product used in a farmer’s field.
  • Durham’s Deep Blue Medical Advances, founded in 2014 by a plastic surgeon as an incubator for developing Duke medical device inventions, is the sole bioscience-related semifinalist in the spring 2016 round of NC IDEA grants.
  • A pioneering researcher at North Carolina State University, Rodolphe Barrangou, Ph.D., will tell the public Monday evening how he’s cutting and pasting his way to new discoveries in the adaptive bacterial immune system known as CRISPR.
  • Medical Murray is celebrating 20 years of innovation and expansion in the medical device industry on April 1, 2016, mere months after open house festivities at a new Medical Murray Southeast building near the Charlotte Douglas International Airport.
  • Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there.
  • Morris Clarke, Ph.D., associate professor of biochemistry at Winston-Salem State University, has been named leader of the Executive Council of the Advisory Committee for Biotechnology in the Piedmont Triad as new members also join the advisory committee.
  • Duke University has purchased an exclusive sublicense from former NC biotech company PhaseBio Pharmaceuticals to use some of the firm's technology in developing long-acting cancer drugs with minimal toxic side effects.
  • Doug Edgeton, president and CEO of the North Carolina Biotechnology Center, is among a dozen corporate leaders nominated for a 2016 “Full Steam Ahead” award in a contest sponsored by WRAL TechWire.
  • Morrisville-based Envisia Therapeutics, a clinical-stage biotechnology company focused on developing novel therapies for eye diseases, has raised $16.5 million in additional Series A financing from existing investors.
  • Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in Durham that will create 52 new jobs.
  • Craft Technologies, a small contract laboratory in Wilson, has received $844,395 from the Bill & Melinda Gates Foundation for analytical work aimed at improving nutrition in the developing world.
  • Almac Group, a global CRO based in Northern Ireland, has opened a new development facility for companion diagnostics in Durham.
  • A family-owned German company called Raumedic has opened a $27 million development and production facility in western North Carolina to make medical and pharmaceutical plastic and rubber components.
  • Blood therapeutics company Grifols said it will invest $210 million to build two new facilities at its Clayton campus.
  • The federal faucet is opening again to pour $25.5 million into solithromycin, a promising drug being developed by Cempra, a Chapel Hill company that has declared war on bacterial infections.  
  • Durham-based BioCryst Pharmaceuticals might have a Zika bazooka on its hands, because the company’s experimental broad spectrum antiviral drug BCX4430 saved the lives of a batch of lab mice whose immune systems were deliberately suppressed before they were infected with Zika virus.
  • OncoTAb, a Charlotte company developing cancer diagnostics technologies with help from a North Carolina Biotechnology Center loan, is the only North Carolina life science company among the 60 startups and emerging companies have made the cut to present at this year’s Southeast Venture Conference.
  • NCBiotech President and CEO Doug Edgeton did some prognosticating at a luncheon briefing preceding Tuesday’s opening of the two-day 2016 CED Life Science Conference at the Raleigh Convention Center, presented each year by CED in partnership with NCBiotech and NCBio.


Subscribe to News & Events